Development of Cathepsin B-Responsive GalNAc-PROTACs for Hepatocyte-Targeting Protein Degradation
Authors:
- 16 December 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Abstract
Targeted protein degradation (TPD) has arisen as a therapeutic revolution for eliminating disease-relevant proteins, but its tissue-specific delivery remains a critical challenge. Here, we developed an asialoglycoprotein receptor (ASGPR)-based platform for the selective degradation of target proteins in hepatocytes. By conjugating the ASGPR ligand triantennary N-acetylgalactosamine (tri-GalNAc) with a BRD4-targeted proteolysis targeting chimera (PROTAC) via a cathepsin B (CTSB)-cleavable Val-Cit-PABC linker, we generated a prototype GalNAc-PROTAC conjugate, TMU454. TMU454 selectively degraded BRD4 in ASGPR-positive hepatocellular carcinoma cells while sparing ASGPR-negative cancer cells and normal cells. Mechanistic investigations confirmed that TMU454-mediated BRD4 degradation is dependent on the ASGPR-mediated endocytosis, CTSB-mediated linker cleavage, and ubiquitin-proteasome system (UPS). Furthermore, a fluorescein-labeled analogue, TMU670, revealed preferential liver accumulation. Importantly, TMU454 significantly inhibited tumor growth in a Huh7-derived liver cancer xenograft model without apparent systemic toxicity. Collectively, this study establishes a versatile approach for tissue-selective protein degradation and advances targeted therapies for liver cancer.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC3404102)
- Tianjin Municipal Science and Technology Bureau (23JCQNJC00940)
- National Natural Science Foundation of China (82204223)
- National Natural Science Foundation of China (82372899)
This publication has 39 references indexed in Scilit:
- Global landscape of PROTAC: Perspectives from patents, drug pipelines, clinical trials, and licensing transactionsEuropean Journal of Medicinal Chemistry, 2025
- Liver-targeting chimeras as a potential modality for the treatment of liver diseasesJournal of Controlled Release, 2024
- Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniquesEuropean Journal of Medicinal Chemistry, 2023
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast CancerAngewandte Chemie International Edition, 2021
- Antibody–drug conjugates: Recent advances in linker chemistryActa Pharmaceutica Sinica B, 2021
- Inclisiran: First ApprovalDrugs, 2021
- Givosiran: First ApprovalDrugs, 2020
- Aberrant Super‐Enhancer Landscape in Human Hepatocellular CarcinomaHepatology, 2019
- Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applicationsJournal of Controlled Release, 2015
- Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cellsJournal of Controlled Release, 2008